COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

Compass Pathways Appoints Kelley Boucher as Chief People Officer

September 30, 2026

Performance

52-Week Range 27.4% below 52-week high

11.53

4.8852W Low 15.8752W High

1 Week 14.6% below 1-week high

11.631W Low 13.491W High

COMPASS Pathways Plc - American Depository Shares (CMPS) traded between $4.88 and $15.87 over the past 52 weeks and last traded at $11.53, 27.4% below its 52-week high. Over the past week it ranged between $11.63 and $13.49.

Past 12 Months

-12.9%

-13.1%

-10.2%

+100.4%

+76.0%

+83.2%

1W -$1.71

1M -$1.74

3M -$1.31

6M +$5.78

YTD +$4.98

1Y +$5.24

CMPS was +83.2% over the past year, +100.4% over six months, +76.0% year to date, -12.9% in the last week.

12 Months vs Market

CMPS

+83.2%

DIA

+9.5%

SPY

+15.2%

QQQ

+24.0%

IWM

+14.7%

Over the past 12 months CMPS returned +83.2% versus DIA (Dow) +9.5%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +24.0% and IWM (Russell 2000) +14.7%.

Volume & Liquidity 0.43× 3-mo avg

Today 1,427,961 3-mo avg 3.3M

2.8M

3.0M

3.3M

3.8M

YTD

3.5M

3.1M

CMPS most recently traded 1,427,961 shares against a 3-month average daily volume of 3.3M.

More News

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch ↗

September 24, 2026

Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss ↗

August 05, 2026

Via Chartmill

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data ↗

September 22, 2026

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗

September 22, 2026

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears ↗

September 22, 2026

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

September 16, 2026

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

September 15, 2026

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

September 10, 2026

Compass Pathways to Participate in Investor Conferences the Week of September 14th

September 10, 2026

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

September 09, 2026

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

September 08, 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2026

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

September 02, 2026

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

September 01, 2026

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances ↗

August 12, 2026

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

August 06, 2026

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

August 06, 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 05, 2026

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

From USA News Group

Via GlobeNewswire

Compass Pathways Q2 Earnings Call Highlights ↗

August 05, 2026

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

August 05, 2026

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

July 29, 2026